Statement Of Cash Flows [Abstract]

Transgene - Filing #2810948

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities
34 671 EUR
20 303 EUR
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities
34 572 EUR
20 272 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
- EUR
- EUR
Payments of lease liabilities, classified as financing activities
1 192 EUR
1 281 EUR
Proceeds from government grants, classified as financing activities
- EUR
455,000 EUR
Cash flows from (used in) financing activities
11 369 EUR
1 477 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
7,000 EUR
- EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
11 263 EUR
1 508 EUR
Cash and cash equivalents
15 666 EUR
4 403 EUR
5 911 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.